Ask AI
ProCE Banner Activity

CE / CME

EU Expert Think Tank: Global Perspectives and Clinical Resources to Optimize Antibody–Drug Conjugate Therapies in Metastatic HR-Positive/HER2-Negative or TNBC 

Video

Increase your confidence in the use of antibody–drug conjugates for patients with HR-positive/HER2-negative or triple-negative metastatic breast cancer by reviewing the latest clinical trial data, current treatment guidelines, and toxicity management through certified micro-text modules, downloadable slides, and a ClinicalThought expert commentary.

Physicians: Maximum of 0.25 AMA PRA Category 1 Credit

European Learners: 0.25 EBAC® CE Credit

Released: August 13, 2026

Expiration: February 12, 2027

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

This activity is supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Target Audience

This educational activity is intended for European oncologists and other healthcare professionals who care for patients with metastatic TNBC or HR+/HER2− MBC.

Program Learning Goal

This educational activity aims to improve European learners’ knowledge, competence, and confidence in aligning antibody–drug conjugate therapy of metastatic TNBC and HR+/HER2− MBC in clinical practice with evolving guidelines, new data, and best practices, with the goal of improving outcomes and decreasing the risk of further progression.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Summarize current and emerging clinical evidence supporting the use of TROP2-directed antibody–drug conjugates in metastatic TNBC or HR+/HER2− MBC with a focus on best practices in Europe

  • Identify appropriate candidates with metastatic TNBC or HR+/HER2− MBC for treatment with TROP2-directed ADCs based on disease characteristics, prior therapy exposure, comorbidities, and patient goals

Financial Disclosures

Decera Clinical Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to Decera Clinical Education policy. Decera Clinical Education is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Peter Schmid, MD, PhD, FRCP: consultant/advisor/speaker: AstraZeneca, Bayer, Boehringer Ingelheim, Celgene, Eisai, Merck, Novartis, Pfizer, Roche.

The planners and content peer reviewers from Decera Clinical Education do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from August 13, 2026, through February 12, 2027:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Additional Disclosures

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Generative artificial intelligence (AI) tools were used for revising or refining educational content. All AI-assisted content underwent human review, editing, and validation by qualified faculty and accredited education staff to ensure scientific accuracy, balance, and compliance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC dba Decera Clinical Education is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Clinical Care Options, LLC dba Decera Clinical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

EBAC Accreditation 

Clinical Care Options, LLC dba Decera Clinical Education is an EBAC® accredited provider since 2025 

This program is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) for 0.25 hours of effective education time. 

EBAC® holds an agreement on mutual recognition of substantive equivalency with the US Accreditation Council for CME (ACCME) and the Royal College of Physicians and Surgeons of Canada, respectively. 

Through an agreement between the European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) and the American Medical Association, physicians may convert EBAC® External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC® credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™. 

EBAC® is a member of the International Academy for CPD Accreditation (IACPDA), the World Federation for Medical Education (WFME) CPD Recognition Committee, and a partner member of the International Association of Medical Regulatory Authorities (IAMRA). 

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.